A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels,...

Descripción completa

Detalles Bibliográficos
Autores principales: Suchowerska, Alexandra K., Stokman, Geurt, Palmer, James T., Coghlan, Phillip A., Pieterman, Elsbet J., Keijzer, Nanda, Lambert, Gilles, Chemello, Kevin, Jaafar, Ali K., Parmar, Jasneet, Yan, Liping, Tong, Yingtao, Mu, Lin, Princen, Hans M.G., Bonnar, James, Evison, Benny J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646673/
https://www.ncbi.nlm.nih.gov/pubmed/36209894
http://dx.doi.org/10.1016/j.jlr.2022.100293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646673/
https://www.ncbi.nlm.nih.gov/pubmed/36209894
http://dx.doi.org/10.1016/j.jlr.2022.100293

Ejemplares similares